NASDAQ:ADMPAdamis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.58 +0.06 (+11.54 %) (As of 07/10/2020 01:14 PM ET) Add Compare Share Today's Range$0.51Now: $0.58▼$0.6050-Day Range$0.47MA: $0.55▼$0.6652-Week Range$0.27Now: $0.58▼$1.54Volume3.80 million shsAverage Volume1.67 million shsMarket Capitalization$42.77 millionP/E RatioN/ADividend YieldN/ABeta2 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAdamis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.20, Adamis Pharmaceuticals has a potential upside of 106.4% from its current price of $0.58.Amount of Analyst CoverageAdamis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesAdamis Pharmaceuticals has received 330 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdamis Pharmaceuticals has received 206 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdamis Pharmaceuticals has received 61.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdamis Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdamis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adamis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Adamis Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 15.69% of the stock of Adamis Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adamis Pharmaceuticals are expected to grow in the coming year, from ($0.29) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adamis Pharmaceuticals is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adamis Pharmaceuticals is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdamis Pharmaceuticals has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMP Previous Symbol CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone858-997-2400Debt Debt-to-Equity Ratio0.04 Current Ratio1.45 Quick Ratio1.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.11 million Price / Sales1.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book1.00Profitability EPS (Most Recent Fiscal Year)($0.55) Net Income$-29,310,000.00 Net Margins-140.34% Return on Equity-76.02% Return on Assets-56.45%Miscellaneous Employees152 Outstanding Shares73,730,000Market Cap$42.77 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ADMP Rates by TradingView Receive ADMP News and Ratings via Email Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter. Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions How has Adamis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Adamis Pharmaceuticals' stock was trading at $0.4029 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADMP stock has increased by 44.3% and is now trading at $0.5814. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Adamis Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adamis Pharmaceuticals. When is Adamis Pharmaceuticals' next earnings date? Adamis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Adamis Pharmaceuticals. How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced its quarterly earnings data on Monday, May, 18th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.11. The specialty pharmaceutical company had revenue of $4.66 million for the quarter, compared to analyst estimates of $6.87 million. Adamis Pharmaceuticals had a negative return on equity of 76.02% and a negative net margin of 140.34%. View Adamis Pharmaceuticals' earnings history. What price target have analysts set for ADMP? 4 brokers have issued 1-year price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.50. On average, they expect Adamis Pharmaceuticals' share price to reach $1.20 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price. View analysts' price targets for Adamis Pharmaceuticals. Has Adamis Pharmaceuticals been receiving favorable news coverage? Headlines about ADMP stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Adamis Pharmaceuticals. Who are some of Adamis Pharmaceuticals' key competitors? Some companies that are related to Adamis Pharmaceuticals include Cerecor (CERC), Aquestive Therapeutics (AQST), Corvus Pharmaceuticals (CRVS), Tyme Technologies (TYME), Evelo Biosciences (EVLO), Obseva (OBSV), KITOV PHARMA LT/S (KTOV), Mustang Bio (MBIO), InflaRx (LUMO), Minerva Neurosciences (NERV), BIOFRONTERA AG/ADR (BFRA), Inflarx (IFRX), Iterum Therapeutics (NRBO), PhaseBio Pharmaceuticals (PHAS) and CELYAD SA/ADR (CYAD). View all competitors. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), SCYNEXIS (SCYX), Clovis Oncology (CLVS) and Corbus Pharmaceuticals (CRBP). Who are Adamis Pharmaceuticals' key executives? Adamis Pharmaceuticals' management team includes the following people: Mr. Richard C. Williams, Chairman & Consultant (Age 75)Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)Mr. Robert B. Rothermel, Consultant & Director (Age 75) What is Adamis Pharmaceuticals' stock symbol? Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP." How do I buy shares of Adamis Pharmaceuticals? Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adamis Pharmaceuticals' stock price today? One share of ADMP stock can currently be purchased for approximately $0.58. How big of a company is Adamis Pharmaceuticals? Adamis Pharmaceuticals has a market capitalization of $42.87 million and generates $22.11 million in revenue each year. The specialty pharmaceutical company earns $-29,310,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe. What is Adamis Pharmaceuticals' official website? The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com. How can I contact Adamis Pharmaceuticals? Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
